Overview
- Recruitment has begun at up to 10 UK sites as part of a global plan to enroll about 180 people recently diagnosed with multiple sclerosis.
- The University of Edinburgh leads the Horizon trial with sponsorship from Moderna.
- Eligible participants are aged 18 to 55, have an MS diagnosis within the past two years, and will be followed for roughly two and a half years to track new disease activity.
- The investigational vaccine trains the immune system to make a viral protein so it can keep Epstein–Barr virus suppressed.
- Health leaders and the MS Society welcomed the study, with the UK the first country outside the US to open it, while any future role for population vaccination to prevent MS remains unproven.